Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionBank of New York Mellon Corp
Latest Disclosed Ownership217,226 shares
Latest Disclosed Value $ 6,453,782
Bank of New York Mellon Corp reports 1.26% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 5, 2026 - Bank of New York Mellon Corp filed a 13F-HR form disclosing ownership of 217,226 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $6,453,784 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 219,996 shares of Travere Therapeutics, Inc.. This represents a change in shares of -1.26% during the quarter. The current value of the position is $9,818,615 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 217,226 -2,770 -1.26 6,454 -23.23 0.0001
2026-02-10 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 219,996 -17,247 -7.27 8,406 48.25 0.0015
2025-11-03 2025-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 237,243 6,098 2.64 5,670 65.79 0.0010
2025-08-05 2025-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 231,145 -2,797 -1.20 3,421 -18.42 0.0006
2025-04-29 2025-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 233,942 17,079 7.88 4,192 10.99 0.0008
2025-02-04 2024-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 216,863 7,513 3.59 3,778 29.00 0.0007
2024-11-12 2024-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 209,350 -55,466 -20.95 2,929 34.56 0.0005
2024-07-25 2024-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 264,816 41,048 18.34 2,177 26.14 0.0004
2024-04-25 2024-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 223,768 -14,232 -5.98 1,725 -19.35 0.0003
2024-01-29 2023-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 238,000 -7,978 -3.24 2,140 -2.73 0.0004
2023-10-24 2023-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 245,978 -2,168 -0.87 2,199 -42.30 0.0005
2023-08-03 2023-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 248,146 31,377 14.47 3,812 -21.83 0.0008
2023-05-09 2023-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 216,769 3,546 1.66 4,875 8.72 0.0011
2023-02-14 2022-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 213,223 -895 -0.42 4,484 -15.01 0.0010
2022-11-14 2022-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 214,118 23,617 12.40 5,276 14.32 0.0013
2022-08-15 2022-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 190,501 -30,286 -13.72 4,615 -18.88 0.0011
2022-05-11 2022-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 220,787 -1,301 -0.59 5,689 -17.48 0.0011
2022-02-11 2021-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 222,088 -1,162 -0.52 6,894 27.36 0.0012
2021-11-18 2021-09-30 13F/A-1 TRAVERE THERAPEUTICS COM 89422G107 223,250 19,796 9.73 5,413 82.32 0.0011
2021-11-12 2021-09-30 13F TRAVERE THERAPEUTICS COM 89422G107 223,250 19,796 5,413 0.0001
2021-08-11 2021-06-30 13F TRAVERE THERAPEUTICS COM 89422G107 203,454 -2,958 -1.43 2,969 -42.39 0.0006
2021-05-13 2021-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 206,412 10,723 5.48 5,154 -3.37 0.0011
2021-02-09 2020-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 195,689 4,112 2.15 5,334 50.81 0.0012
2020-11-12 2020-09-30 13F RETROPHIN COM 761299106 191,577 10,632 5.88 3,537 -4.22 0.0009
2020-08-12 2020-06-30 13F RETROPHIN COM 761299106 180,945 -5,847 -3.13 3,693 35.52 0.0010
2020-05-06 2020-03-31 13F RETROPHIN COM 761299106 186,792 47 0.03 2,725 2.75 0.0009
2020-02-14 2019-12-31 13F RETROPHIN COM 761299106 186,745 6,208 3.44 2,652 26.77 0.0007
2019-11-07 2019-09-30 13F RETROPHIN COM 761299106 180,537 2,272 1.27 2,092 -41.58 0.0006
2019-08-12 2019-06-30 13F RETROPHIN COM 761299106 178,265 -2,461 -1.36 3,581 -12.44 0.0010
2019-05-14 2019-03-31 13F RETROPHIN COM 761299106 180,726 2,697 1.51 4,090 1.51 0.0011
2019-02-11 2018-12-31 13F RETROPHIN COM 761299106 178,029 -180,708 -50.37 4,029 -60.91 0.0013
2018-11-09 2018-09-30 13F RETROPHIN COM 761299106 358,737 -3,286 -0.91 10,306 4.43 0.0026
2018-08-06 2018-06-30 13F RETROPHIN COM 761299106 362,023 -23,680 -6.14 9,869 14.42 0.0027
2018-05-15 2018-03-31 13F RETROPHIN COM 761299106 385,703 -10,048 -2.54 8,625 3.43 0.0024
2018-02-09 2017-12-31 13F RETROPHIN COM 761299106 395,751 -48,067 -10.83 8,339 -24.51 0.0022
2017-11-06 2017-09-30 13F RETROPHIN COM 761299106 443,818 9,119 2.10 11,046 31.05 0.0030
2017-08-03 2017-06-30 13F RETROPHIN COM 761299106 434,699 46,967 12.11 8,429 17.77 0.0024
2017-05-03 2017-03-31 13F RETROPHIN COM 761299106 387,732 -4,559 -1.16 7,157 -3.64 0.0020
2017-02-13 2016-12-31 13F RETROPHIN COM 761299106 392,291 -22,216 -5.36 7,427 -19.93 0.0021
2016-11-03 2016-09-30 13F RETROPHIN COM 761299106 414,507 -108,199 -20.70 9,276 -0.37 0.0028
2016-08-01 2016-06-30 13F RETROPHIN COM 761299106 522,706 -16,188 -3.00 9,310 26.46 0.0028
2016-05-16 2016-03-31 13F/A-1 RETROPHININC COM 761299106 538,894 32,751 6.47 7,362 -24.59 0.0022
2016-05-11 2016-03-31 13F RETROPHININC COM 761299106 538,894 7,362
2016-02-12 2015-12-31 13F RETROPHIN COM 761299106 506,143 81,270 19.13 9,763 13.43 0.0030
2015-11-10 2015-09-30 13F RETROPHIN COM 761299106 424,873 -29,862 -6.57 8,607 -42.91 0.0026
2015-08-06 2015-06-30 13F RETROPHININC COM 761299106 454,735 331,392 268.68 15,075 410.15 0.0042
2015-08-28 2015-03-31 13F/A-1 RETROPHIN COM 761299106 123,343 22,317 22.09 2,955 139.08 0.0008
2015-05-13 2015-03-31 13F RETROPHIN COM 761299106 123,343 2,955
2015-08-28 2014-12-31 13F/A-2 RETROPHIN COM 761299106 101,026 -1,081 -1.06 1,236 34.20 0.0003
2015-02-17 2014-12-31 13F RETROPHIN COM 761299106 101,026 1,236
2014-11-18 2014-09-30 13F/A-1 RETROPHIN COM 761299106 102,107 21,992 27.45 921 -2.13 0.0003
2014-11-13 2014-09-30 13F RETROPHIN COM 761299106 102,107 921
2015-08-28 2014-06-30 13F/A-1 RETROPHIN COM 761299106 80,115 28,325 54.69 941 -14.30 0.0003
2014-08-12 2014-06-30 13F RETROPHIN COM 761299106 80,115 941
2014-05-14 2014-03-31 13F RETROPHIN COM 761299106 51,790 51,790 1,098 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.